Letters to the Editor

Case Report: Patient with Ketoacidosis and Impaired Insulin Secretion


Am Fam Physician. 2011 Feb 1;83(3):232.

Original Article: Diabetes Mellitus: Diagnosis and Screening

Issue Date: April 1, 2010

Available at: https://www.aafp.org/afp/2010/0401/p863.html

Original Article: Latent Autoimmune Diabetes in Adults [Editorial]

Issue Date: April 1, 2010

Available at: https://www.aafp.org/afp/2010/0401/p843.html

to the editor: We read with interest the article by Drs. Patel and Macerollo on diabetes mellitus, and the accompanying editorial by Dr. Unger discussing latent autoimmune diabetes in adults (LADA). LADA is one of several distinct syndromes now classified as ketosisprone diabetes.1 We recently cared for a patient with newly diagnosed diabetes and ketoacidosis whose clinical and laboratory profile was not typical for type 1 diabetes, type 2 diabetes, or LADA. The 37-year-old man had no notable medical history and no primary care physician when he presented to the emergency department after several days of low-grade fever, nausea, and polyuria. Laboratory evaluation revealed severe ketoacidosis (venous pH, 6.99; plasma glucose, 416 mg per dL [23.09 mmol per L]; serum bicarbonate, 6 mEq per L [6.00 mmol per L]; anion gap, 22 mEq per L; serum ketones, positive). The patient was treated with hydration and intravenous insulin, and, after resolution of the acidosis, with subcutaneous insulin.

The patient was overweight but not obese (height, 6 ft, 0 in [183 cm]; weight, 217.78 lb [98 kg], body mass index, 29.4 kg per m2). During his hospitalization, the patient's blood pressure was below 140/80 mm Hg except for a single elevated reading on presentation to the emergency department. His mother had previously been diagnosed with diabetes. His A1C level was 15.7 percent, suggesting a period of asymptomatic hyperglycemia before his acute presentation. His C-peptide level was 0.6 ng per mL (0.20 nmol per L; normal range, 0.8 to 3.5 ng per mL [0.26 to 1.16 nmol per L]). Testing was negative for antibodies to glutamic acid decarboxylase, tyrosine kinase, insulin, and islet-cell. Blood cultures were sterile, and a urine culture grew Staphylococcus epidermidis, Klebsiella pneumoniae, and Group B streptococci, probably representing contamination.

The patient had unequivocal ketoacidosis and impaired insulin secretion without evidence of autoimmunity. Although chronic hyperglycemia in the setting of insulin resistance can cause beta cell exhaustion in the absence of autoimmunity,2 common manifestations of insulin resistance such as hypertension and obesity were absent in this patient. Alternatively, he may have had an atypical presentation of LADA in which the initial insulin-independent phase did not come to clinical attention. Although glutamic acid decarboxylase (GAD-65) autoantibody positivity is a sensitive predictor of insulin dependence,3 novel autoantibodies have also been associated with beta cell destruction.4 This case illustrates the heterogeneous nature of ketosis-prone diabetes, and the need for more research on this subject.

Author disclosure: Nothing to disclose.


show all references

1. Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev. 2008;29(3):292–302....

2. Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord. 2008;9(4):329–343.

3. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care. 1995;18(12):1557–1565.

4. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA. 2007;104(43):17040–17045.

Send letters to afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.



Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Jan 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article